# Vivos Therapeutics (VVOS) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/VVOS
## Company Profile
- Ticker: VVOS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 0.3406 USD
- Market cap: 9423317.72 USD
- Last updated: 2026-08-05
## Business Overview
### Sleep-Disordered Breathing Technology
Vivos Therapeutics is a medical technology and healthcare-services company focused on obstructive sleep apnea, snoring, and related chronic conditions. It combines oral appliances, diagnostic workflows, and sleep-center partnerships to improve identification and treatment of OSA.
### CARE Devices and the Vivos Method
The company’s Complete Airway Repositioning and Expansion devices have received FDA 510(k) clearance for adults across OSA severity levels and for moderate-to-severe OSA in children ages six through 17. Vivos integrates these devices with clinical protocols through the Vivos Method.
### Provider and Sleep-Center Integration
Vivos works with dentists, physicians, and sleep centers to identify patients and deliver treatment. The acquisition of The Sleep Center of Nevada gives the company a direct clinical-services platform alongside its device business.
### Service-Enabled Commercial Model
Revenue opportunities include oral-appliance sales, clinical education, diagnostic and sleep services, and support for insurance reimbursement. This model combines medical technology with a provider network rather than relying solely on standalone device sales.
## Why The Stock Is Moving

Following the latest company update, “Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology”, VVOS closed down 26.3% at $0.3406 on Aug 5, 2026. The move occurred in the trading session associated with this company update.

## Future Catalysts

- Vivos Therapeutics’s catalysts are sleep-apnea device adoption, reimbursement, and broader dental-sleep workflow penetration. The story improves as the installed base becomes more durable.

## Recent News
- 2026-08-05 12:30 EST — [Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology](https://biopharmsignal.com/news/VVOS/vivos-therapeutics-announces-issuance-of-new-us-patent-broadening-protection-for-2866528c) — Source: Vivos Therapeutics
- 2026-06-30 12:45 EST — [Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants](https://biopharmsignal.com/news/VVOS/vivos-vida-appliance-shows-statistically-significant-improvement-in-insomnia-sev-76ccf0ec) — Source: Vivos Therapeutics
- 2026-06-22 12:30 EST — [Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity](https://biopharmsignal.com/news/VVOS/vivos-therapeutics-and-streeterville-extend-timeframe-of-strategic-financing-agr-76425cab) — Source: Vivos Therapeutics
- 2026-06-11 12:30 EST — [Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering](https://biopharmsignal.com/news/VVOS/vivos-therapeutics-announces-intent-to-file-a-registration-statement-for-a-propo-e20065b2) — Source: Vivos Therapeutics
- 2026-06-10 13:03 EST — [Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients](https://biopharmsignal.com/news/VVOS/vivos-therapeutics-announces-key-collaboration-agreement-with-multi-location-flo-8a573b10) — Source: Vivos Therapeutics